Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gritstone Bio Inc.
Headquarters: Emeryville, CA, United States of America
Website: https://gritstonebio.com/
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Vassiliki Celia Economides
Number Of Employees: 231
Enterprise Value: $258,878,194
PE Ratio: 0
Exchange/Ticker 1: NASDAQ:GRTS
Exchange/Ticker 2: N/A
Latest Market Cap: $11,800
BioCentury | Jan 31, 2025
Management Tracks
Takeda makes waves again with CEO pick
Plus: Roche hires a chief digital technology officer, and updates from Gain, Allogene, Airna, Osta and more
BioCentury | Jan 17, 2025
Finance
4Q24 Wrap: They all fall down
Winners, losers in biotech stock tiers in 4Q24
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 10, 2025
Management Tracks
Odyssey hires Jason Haas as CFO
Plus: CMO changes at Centessa, Lifordi, Rapport and Gemma, and updates from Peptone, Labgenius, Mitorx and more
BioCentury | Apr 6, 2024
Finance
Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo
Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM
BioCentury | Oct 14, 2023
Finance
Oct. 13 Quick Takes: Pfizer trims guidance, cutting costs by $3.5B due to COVID product sales
Plus: FDA approves Pfizer’s ulcerative colitis therapy from Arena deal and updates from Lilly, Novo, Harmony and more
BioCentury | Sep 29, 2023
Regulation
Sept. 28 Quick Takes: FDA approves Amicus’ Pompe disease therapy
Plus: J&J’s Rybrevant raises the bar and updates from Harbinger, Gritstone, Merck, Immunovant, Evozyne, PTC
BioCentury | Sep 28, 2023
Management Tracks
Expanded role for Gaito at J.P. Morgan
Plus: Peptone hires a new CSO, names Gritstone’s Allen chair, and updates from Foresite, OncoC4, Sibylla, Cell-Easy and Photocure
BioCentury | May 2, 2023
Management Tracks
Azam named CEO at Inspirna
Plus: Day One promotes Blackman to head of R&D, and updates from Esperovax, Ring, Alladapt, Innoviva and more
BioCentury | Dec 17, 2022
Product Development
Neoantigens Part III: Picking up the pace
The field ends a busy 4Q22 with Moderna’s highly anticipated, heavily scrutinized data
Items per page:
1 - 10 of 25